Floatz logo

Futibatinib

Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors

Taiho Oncology, Inc.Small moleculePhase 1/2Dormant
CCC
49/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
34/ 100
Competitive Position
95/ 100

Competitive context

928 Active assets in the Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors cohort.

Asset / SponsorPhaseRating
PANITUMUMAB
Astellas Pharma Inc
Phase 2BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Sanofi
Phase 4BB
Inno-206
The First Affiliated Hospital of Soochow University
Phase 2/3BB
DINITROGEN MONOXIDE
Medical College of Wisconsin
Phase 4BB
Glycopyrrolate
Medical College of Wisconsin
Phase 4BB

View all 50 →

Same molecule, other indications

Futibatinib is also rated in:

Advanced or Metastatic Solid TumorDormant
CCC
Indicative ·
54 / 100
View asset →
hepatocellular carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
metastatic malignant neoplasmDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →